Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PLX-PAD Low dose · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| PLX-PAD Low dose | EXPERIMENTAL | PLX-PAD double low doses |
| PLX-PAD high doses | ACTIVE_COMPARATOR | PLX-PAD double high dose |
| Placebo | PLACEBO_COMPARATOR | Double Placebo doses |
| PLX-PAD high dose +Placebo | EXPERIMENTAL | High dose+Placebo |
| Name | Type | Description |
|---|---|---|
| PLX-PAD Low dose | BIOLOGICAL | - |
| PLX-PAD high doses | BIOLOGICAL | - |
| Double Placebo | BIOLOGICAL | - |
| high dose +Placebo | BIOLOGICAL | - |
Inclusion Criteria: * Adult male or female subjects between 45 to 85 years of age (inclusive) at the time of screening visit. * Subjects with a diagnosis of peripheral artery disease, secondary to atherosclerosis, confirmed by one of the following criteria assessed at the screening visit: * Rest...
PLX-PAD is an investigational cell therapy being studied for Critical Limb Ischemia (CLI), Intermittent Claudication, Hip Fracture, and Peripheral Artery Disease. It is administered by intramuscular injection and is being developed by Pluri Inc. (PLUR). The drug is currently in Phase 3 clinical trials.
PLX-PAD is a placental-derived cell therapy, not a monoclonal antibody. It is designed to promote tissue repair and regeneration in ischemic conditions such as Critical Limb Ischemia and Peripheral Artery Disease. The therapy works by delivering allogeneic cells that support angiogenesis and muscle recovery.
PLX-PAD is being developed by Pluri Inc., a biopharmaceutical company traded on the stock exchange under the ticker PLUR. The company is conducting Phase 3 clinical trials for the treatment of Critical Limb Ischemia and Hip Fracture.
PLX-PAD is currently in Phase 3 clinical development. It has completed two Phase 1 safety trials and two Phase 3 efficacy trials. The drug is investigational and has not been approved by regulatory authorities for any indication.
PLX-PAD has completed several clinical trials, including NCT00919958 and NCT00951210, which were Phase 1 safety studies in Critical Limb Ischemia. Phase 3 trials include NCT03006770 for Critical Limb Ischemia with minor tissue loss and NCT03451916 for muscle injury following hip fracture surgery.
Yes, PLX-PAD is also referred to as PLX-PAD cells in clinical trial documentation. The drug is an allogeneic cell therapy derived from placental cells, and the terms are used interchangeably in the context of its development for peripheral artery disease and related conditions.